Regeneron Pharmaceuticals will report Q4 and full year 2025 results on January 30, 2026, with a conference call at 8:30 AM ET.
Quiver AI Summary
Regeneron Pharmaceuticals, Inc. announced that it will release its financial and operational results for the fourth quarter and full year 2025 on January 30, 2026, before the U.S. markets open. The company will hold a conference call and webcast at 8:30 AM Eastern Time the same day, accessible through their website with pre-registration for telephone participants. A replay and transcript will be available online for 30 days. Regeneron is a biotechnology firm focused on developing innovative medicines for serious diseases, leveraging proprietary technologies and insights from their genetics center to advance scientific discovery and drug development.
Potential Positives
- Regeneron will be reporting its fourth quarter and full year 2025 financial results, providing transparency and insights into the company's performance.
- The scheduled conference call demonstrates Regeneron's commitment to investor relations and open communication with stakeholders.
- Regeneron's position as a leading biotechnology company is reinforced by its focus on developing life-transforming medicines for a wide range of serious diseases.
- The mention of proprietary technologies and ongoing innovation, such as the VelociSuite® and Regeneron Genetics Center®, highlights the company's commitment to advancing scientific discovery and drug development.
Potential Negatives
- None
FAQ
When will Regeneron announce its Q4 and full year 2025 results?
Regeneron will announce its financial results on January 30, 2026, before U.S. markets open.
How can I access the Regeneron conference call?
You can access the conference call live via webcast on Regeneron’s 'Investors and Media' page.
What time is the Regeneron conference call scheduled?
The conference call is scheduled for 8:30 AM Eastern Time on January 30, 2026.
Will there be a replay of the conference call available?
Yes, a replay and transcript will be archived on Regeneron’s website for at least 30 days.
Where can I find more information about Regeneron?
For more information, visit Regeneron’s official website at www.Regeneron.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$REGN Insider Trading Activity
$REGN insiders have traded $REGN stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $REGN stock by insiders over the last 6 months:
- CHRISTINE A POON has made 0 purchases and 6 sales selling 6,500 shares for an estimated $4,252,745.
- BONNIE L BASSLER sold 760 shares for an estimated $570,000
- JASON PITOFSKY (VP Controller) sold 431 shares for an estimated $280,766
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$REGN Revenue
$REGN had revenues of $3.8B in Q3 2025. This is an increase of 0.9% from the same period in the prior year.
You can track REGN financials on Quiver Quantitative's REGN stock page.
$REGN Congressional Stock Trading
Members of Congress have traded $REGN stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 11/18.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$REGN Hedge Fund Activity
We have seen 637 institutional investors add shares of $REGN stock to their portfolio, and 526 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 2,288,699 shares (-72.3%) from their portfolio in Q3 2025, for an estimated $1,286,866,786
- FMR LLC removed 1,391,216 shares (-41.8%) from their portfolio in Q3 2025, for an estimated $782,239,020
- DODGE & COX added 724,562 shares (+18.9%) to their portfolio in Q3 2025, for an estimated $407,399,475
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 627,905 shares (+73.0%) to their portfolio in Q3 2025, for an estimated $353,052,144
- AQR CAPITAL MANAGEMENT LLC added 606,612 shares (+528.7%) to their portfolio in Q3 2025, for an estimated $341,079,729
- CITADEL ADVISORS LLC removed 450,278 shares (-66.2%) from their portfolio in Q3 2025, for an estimated $253,177,811
- BLACKROCK, INC. removed 438,911 shares (-4.7%) from their portfolio in Q3 2025, for an estimated $246,786,487
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$REGN Analyst Ratings
Wall Street analysts have issued reports on $REGN in the last several months. We have seen 8 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 12/04/2025
- HSBC issued a "Buy" rating on 11/24/2025
- Truist Securities issued a "Buy" rating on 11/24/2025
- B of A Securities issued a "Underperform" rating on 10/29/2025
- Guggenheim issued a "Buy" rating on 10/29/2025
- Cantor Fitzgerald issued a "Overweight" rating on 10/29/2025
- Citigroup issued a "Buy" rating on 10/29/2025
To track analyst ratings and price targets for $REGN, check out Quiver Quantitative's $REGN forecast page.
$REGN Price Targets
Multiple analysts have issued price targets for $REGN recently. We have seen 16 analysts offer price targets for $REGN in the last 6 months, with a median target of $775.5.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $768.0 on 12/12/2025
- Mohit Bansal from Wells Fargo set a target price of $745.0 on 12/10/2025
- Evan David Seigerman from BMO Capital set a target price of $850.0 on 12/04/2025
- John Newman from Canaccord Genuity set a target price of $1057.0 on 12/04/2025
- Yifeng Liu from HSBC set a target price of $890.0 on 11/24/2025
- Gregory Renza from Truist Securities set a target price of $798.0 on 11/24/2025
- Louise Chen from Scotiabank set a target price of $770.0 on 11/24/2025
Full Release
TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at
https://inve
s
t
o
r
.
r
e
generon.com
. To participate via telephone, please register in advance at this
li
n
k
. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ® , which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn , Instagram , Facebook or X .
| Contact Information: | |
| Investor Relations | Corporate Communications |
| Ryan Crowe | Christina Chan |
| 914.847.8790 | 914.847.8827 |
| [email protected] | [email protected] |
